Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
Public ClinicalTrials.gov record NCT03515538. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Study identification
- NCT ID
- NCT03515538
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin for injection Drug
- RRx-001 Drug
- Radiation Therapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 11, 2018
- Primary completion
- Oct 21, 2019
- Completion
- Oct 7, 2020
- Last update posted
- Nov 3, 2024
2018 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| John Wayne Cancer Institute @ Providence St. John's Health Center | Santa Monica | California | 90401 | — |
| Centura Health Research Center | Denver | Colorado | 80210 | — |
| George Washington University | Washington D.C. | District of Columbia | 20037 | — |
| Florida Hospital | Orlando | Florida | 32804 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Ballad Health | Johnson City | Tennessee | 37604 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| UT Southwestern | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03515538, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2024 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03515538 live on ClinicalTrials.gov.